Micronized Vaginal Progesterone Dose and Serum Progesterone Thresholds Determine Reproductive Outcomes in Frozen–Thawed Embryo Transfer With Hormone Replacement Therapy
Reproductive Medicine and Biology · 2026-01 · 25 (1)
DOI: 10.1002/rmb2.70039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Medicine and Biology, online erschienen am 12.03.2026. Verfasst von Mami Sekiguchi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine Toho University Tokyo Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the combined effects of micronized vaginal progesterone (P4) dose and achieved serum P4 levels on reproductive outcomes in hormone replacement therapy–frozen embryo transfer (HRT‐FET) cycles by classifying patients according to both parameters.
Methods
This retrospective cohort study analyzed 1137 single good‐quality blastocyst transfers performed between 2017 and 2022. Patients received OneCrinone 90 mg/day, Lutinus 300 mg/day, or Luteum 800 mg/day. Serum P4 levels on the day of embryo transfer (ET) and assisted reproductive technology (ART) outcomes were compared, including dose‐serum P4‐based subgroup analyses. Receiver operating characteristic analysis was used to explore a serum P4 cutoff for clinical pregnancy.
Results
Higher daily doses were associated with increased serum P4 levels and higher implantation, clinical pregnancy, and live birth rates. An exploratory serum P4 cutoff of 13.1 ng/mL on the day of ET was associated with clinical pregnancy, with significantly better outcomes observed in patients with P4 ≥ 13.1 ng/mL. Dose‐serum P4‐based subgroup analyses showed that both parameters jointly influenced ART outcomes.
Conclusion
In HRT‐FET cycles, achieving adequate micronized vaginal P4 dosage together with sufficient serum P4 levels on the ET day is associated with improved ART outcomes. Monitoring serum P4 may help support individualized luteal phase management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Faculty of Medicine Toho University Tokyo Japan.
- Department of Obstetrics and Gynecology Toho University Omori Medical Center Tokyo Japan.
- Reproduction Center Toho University Omori Medical Center Tokyo Japan.
- Department of Urology Toho University Omori Medical Center Tokyo Japan.
ORCID-Profile: Ayumu Ito, Yukiko Katagiri, Hideyuki Kobayashi, Masahiko Nakata
Zitieren
APA
Sekiguchi, M., Ito, A., Katagiri, Y., Yoneyama, M., Tsuchiya, T., Furui, M., Umemura, N., Kobayashi, H., & Nakata, M. (2026). Micronized Vaginal Progesterone Dose and Serum Progesterone Thresholds Determine Reproductive Outcomes in Frozen–Thawed Embryo Transfer With Hormone Replacement Therapy. Reproductive Medicine and Biology, 25(1). https://doi.org/10.1002/rmb2.70039
Vancouver
Sekiguchi M, Ito A, Katagiri Y, Yoneyama M, Tsuchiya T, Furui M, et al. Micronized Vaginal Progesterone Dose and Serum Progesterone Thresholds Determine Reproductive Outcomes in Frozen–Thawed Embryo Transfer With Hormone Replacement Therapy. Reproductive Medicine and Biology. 2026;25(1). doi:10.1002/rmb2.70039
BibTeX
@article{Sekiguchi2026,
author = {Sekiguchi, Mami and Ito, Ayumu and Katagiri, Yukiko and Yoneyama, Masato and Tsuchiya, Takahiro and Furui, Mayuko and Umemura, Nahomi and Kobayashi, Hideyuki and Nakata, Masahiko},
title = {Micronized Vaginal Progesterone Dose and Serum Progesterone Thresholds Determine Reproductive Outcomes in Frozen–Thawed Embryo Transfer With Hormone Replacement Therapy},
journal = {Reproductive Medicine and Biology},
year = {2026},
volume = {25},
number = {1},
doi = {10.1002/rmb2.70039}
}
EUVIMED